BTIG Research Reiterates Buy Rating for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research report issued on Tuesday,Benzinga reports. They presently have a $112.00 price target on the medical equipment provider’s stock. BTIG Research’s price objective points to a potential upside of 21.37% from the company’s current price.

A number of other analysts have also commented on ZBH. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $100.00 price objective (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Citigroup decreased their target price on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research report on Thursday, December 11th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Finally, Stifel Nicolaus set a $110.00 price objective on Zimmer Biomet in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $106.10.

Zimmer Biomet Trading Up 2.8%

Shares of ZBH traded up $2.55 during mid-day trading on Tuesday, reaching $92.28. The company had a trading volume of 1,834,863 shares, compared to its average volume of 2,279,722. The firm has a fifty day simple moving average of $90.02 and a 200-day simple moving average of $95.68. The stock has a market cap of $18.29 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 2.29 and a beta of 0.62. Zimmer Biomet has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the previous year, the firm posted $2.31 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently modified their holdings of the business. Legacy Wealth Asset Management LLC lifted its position in Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock worth $460,000 after acquiring an additional 106 shares during the period. Global Retirement Partners LLC lifted its holdings in shares of Zimmer Biomet by 7.0% in the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 111 shares in the last quarter. Cullen Frost Bankers Inc. grew its position in shares of Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Generali Asset Management SPA SGR raised its position in shares of Zimmer Biomet by 0.9% during the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after purchasing an additional 122 shares during the last quarter. Finally, Brookstone Capital Management grew its holdings in Zimmer Biomet by 1.3% during the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock valued at $921,000 after buying an additional 123 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat on both EPS and revenue: reported $2.42 EPS vs. $2.38 consensus and revenue of $2.24B (sales +10.9% year-over-year), reflecting continued demand for orthopedics. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Neutral Sentiment: Revenue and EPS growth were solid vs. prior year, but investors should dig into product/region breakdowns and conference call commentary for sustainability. Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
• Neutral Sentiment: Analyst consensus remains muted—street rating recently shown as a “Hold”—so upgrades/downgrades will matter more than the beat itself for further moves. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of “Hold” by Analysts
• Negative Sentiment: FY2026 guidance was conservative relative to consensus: EPS guidance of $8.30–8.45 (consensus ~8.44) and revenue guidance roughly $8.4B–$8.6B (consensus ~8.6B), which may cap upside if investors expected a clearer beat. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
• Negative Sentiment: Management noted margin contraction in the quarter, which pressures near-term profitability metrics and could weigh on multiple expansion until margin trends reverse. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.